A Trapping Method for Semi-quantitative Assessment of Reactive Metabolite Formation Using [35S]Cysteine and [14C]Cyanide

被引:21
作者
Inoue, Kazuko [1 ]
Shibata, Yoshihiro [1 ]
Takahashi, Hiroyuki [1 ]
Ohe, Tomoyuki [1 ]
Chiba, Masato [1 ]
Ishii, Yasuyuki [1 ]
机构
[1] Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Dept Preclin DMPK, Tsukuba, Ibaraki 3002611, Japan
关键词
reactive metabolites; trapping assay; bioactivation; analytical method; covalent binding; DRUG DESIGN; IMINIUM ION; IN-VITRO; MASS-SPECTROMETRY; GLUTATHIONE; ACTIVATION; IDENTIFICATION; BIOACTIVATION; HEPATOTOXICITY; TROGLITAZONE;
D O I
10.2133/dmpk.24.245
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
A trapping approach for semi-quantitative assessment of bioactivation potential has been established for new chemical entities by using [S-35]cysteine and [C-14]sodium cyanide as trapping reagents. Reactive metabolites were trapped as radioactive adducts with the trapping reagents to be analyzed by radio-LC(/MS). As a reference, hepatotoxic drugs (clozapine, diclofenac, R-(+)-pulegone and troglitazone) were tested in the [S-35]cysteine trapping assay and the proposed structures of the cysteine adducts were consistent with glutathione adducts previously reported. The accuracy of this methodology to predict bioactivation potential of structurally diverse non-radiolabeled test compounds was evaluated by comparing the radiochromatographic peak area obtained in this assays with the extent of covalent binding to protein assessed by the conventional method using radiolabeled test compounds. The value obtained from the [S-35]cysteine trapping assay in human liver microsomes predicted potential for covalent binding of the test compounds to proteins with reasonable accuracy. A combination of trapping reagents ([S-35]cysteine and [C-14]cyanide) improved the accuracy for prediction of bioactivation potential by simultaneously trapping both types of electrophilic reactive metabolites. This method is expected to be a useful to prioritize compounds for further development based on the bioactivation liability, especially at the lead optimization stage.
引用
收藏
页码:245 / 254
页数:10
相关论文
共 35 条
[1]
Reactive intermediates and the pathogenesis of adverse drug reactions: The toxicology perspective [J].
Amacher, DE .
CURRENT DRUG METABOLISM, 2006, 7 (03) :219-229
[2]
Binding of acetaldehyde to a glutathione metabolite: Mass spectrometric characterization of an acetaldehyde-cysteinylglycine conjugate [J].
Anni, H ;
Pristatsky, P ;
Israel, Y .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2003, 27 (10) :1613-1621
[3]
Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS) [J].
Argoti, D ;
Liang, L ;
Conteh, A ;
Chen, LF ;
Bershas, D ;
Yu, CP ;
Vouros, P ;
Yang, E .
CHEMICAL RESEARCH IN TOXICOLOGY, 2005, 18 (10) :1537-1544
[5]
Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology [J].
Baillie, Thomas A. .
CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (07) :889-893
[6]
Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity [J].
Boelsterli, UA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2003, 192 (03) :307-322
[7]
Caldwell GW, 2006, CURR OPIN DRUG DISC, V9, P47
[8]
Day S. H., 2005, Journal of Pharmacological and Toxicological Methods, V52, P278, DOI 10.1016/j.vascn.2004.11.006
[9]
Addressing metabolic activation as an integral component of drug design [J].
Doss, George A. ;
Baillie, Thomas A. .
DRUG METABOLISM REVIEWS, 2006, 38 (04) :641-649
[10]
Evans DC, 2005, CURR OPIN DRUG DISC, V8, P44